Abstract
NUCB2 and its proteolytically cleaved product nesfatin-1 were initially identified as hypothalamic neuroproteins that inhibit food intake, via a leptin-independent pathway. Since then recent studies have found NUCB2/nesfatin-1 to be expressed both centrally, as well as in peripheral tissues. The recent implementation of novel experimental approaches has produced a large body of evidence implicating NUCB2/nesfatin-1 in a diverse range of biological functions and in the modulation of food intake, energy homeostasis and metabolism. In this review, we discuss the discovery of NUCB2 and its proteolytic product nesfatin-1, and its expression in both central and peripheral tissues. In addition we shed light on the most recent discoveries supporting the role for NUCB2/nesfatin-1 in peripheral tissues and its association with metabolic alterations. Moreover, we highlight the importance of NUCB2 and nesfatin-1 in adipose tissue, its regulation of adipogenesis and obesity-associated metabolic diseases.
Keywords: NUCB2, nesfatin-1, obesity, preadipocytes, adipocytes, white adipose tissue, brown adipose tissue and adipogenesis.
Current Pharmaceutical Design
Title:Possible Role of NUCB2/nesfatin-1 in Adipogenesis
Volume: 19 Issue: 39
Author(s): Manjunath Ramanjaneya, Melisande Addison and Harpal S. Randeva
Affiliation:
Keywords: NUCB2, nesfatin-1, obesity, preadipocytes, adipocytes, white adipose tissue, brown adipose tissue and adipogenesis.
Abstract: NUCB2 and its proteolytically cleaved product nesfatin-1 were initially identified as hypothalamic neuroproteins that inhibit food intake, via a leptin-independent pathway. Since then recent studies have found NUCB2/nesfatin-1 to be expressed both centrally, as well as in peripheral tissues. The recent implementation of novel experimental approaches has produced a large body of evidence implicating NUCB2/nesfatin-1 in a diverse range of biological functions and in the modulation of food intake, energy homeostasis and metabolism. In this review, we discuss the discovery of NUCB2 and its proteolytic product nesfatin-1, and its expression in both central and peripheral tissues. In addition we shed light on the most recent discoveries supporting the role for NUCB2/nesfatin-1 in peripheral tissues and its association with metabolic alterations. Moreover, we highlight the importance of NUCB2 and nesfatin-1 in adipose tissue, its regulation of adipogenesis and obesity-associated metabolic diseases.
Export Options
About this article
Cite this article as:
Ramanjaneya Manjunath, Addison Melisande and Randeva S. Harpal, Possible Role of NUCB2/nesfatin-1 in Adipogenesis, Current Pharmaceutical Design 2013; 19 (39) . https://dx.doi.org/10.2174/138161281939131127142959
DOI https://dx.doi.org/10.2174/138161281939131127142959 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Nitric Oxide is a Central Common Metabolite in Vascular Dysfunction Associated with Diseases of Human Pregnancy
Current Vascular Pharmacology Exercise as a platform for pharmacotherapy development in cardiac diseases
Current Pharmaceutical Design Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews Potential Therapeutic Applications of C-Phycocyanin
Current Drug Metabolism Danshen (Salvia miltiorrhiza Bunge): A Prospective Healing Sage for Cardiovascular Diseases
Current Pharmaceutical Design Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Current Drug Targets Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Preclinical Evidence for the Pharmacological Actions of Glycyrrhizic Acid: A Comprehensive Review
Current Drug Metabolism Design, Synthesis and Biological Study of Novel NO-Donor-Caffeic Acid Hybrids as Potential Anti-Atherosclerotic Drug Candidates
Letters in Drug Design & Discovery Potential Therapeutics for Vascular Cognitive Impairment and Dementia
Current Neuropharmacology Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy The Promise of Plant-Derived Substances as Inhibitors of Arginase
Mini-Reviews in Medicinal Chemistry The Effects and Underlying Mechanisms of Cell Therapy on Blood-Brain Barrier Integrity After Ischemic Stroke
Current Neuropharmacology Anti-Inflammatory Responses of Resveratrol
Inflammation & Allergy - Drug Targets (Discontinued) ROS-scavenging and Anti-tyrosinase Properties of Crocetin on B16F10 Murine Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry